143 related articles for article (PubMed ID: 15655368)
1. Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation.
Oki S; Limnander A; Yao PM; Niki M; Pandolfi PP; Rothman PB
Cell Cycle; 2005 Feb; 4(2):310-4. PubMed ID: 15655368
[TBL] [Abstract][Full Text] [Related]
2. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.
Sattler M; Verma S; Pride YB; Salgia R; Rohrschneider LR; Griffin JD
J Biol Chem; 2001 Jan; 276(4):2451-8. PubMed ID: 11031258
[TBL] [Abstract][Full Text] [Related]
3. The phosphatidylinositol polyphosphate 5-phosphatase SHIP1 associates with the dok1 phosphoprotein in bcr-Abl transformed cells.
Dunant NM; Wisniewski D; Strife A; Clarkson B; Resh MD
Cell Signal; 2000 May; 12(5):317-26. PubMed ID: 10822173
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis.
Sattler M; Verma S; Byrne CH; Shrikhande G; Winkler T; Algate PA; Rohrschneider LR; Griffin JD
Mol Cell Biol; 1999 Nov; 19(11):7473-80. PubMed ID: 10523635
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity.
Ng KY; Yin T; Machida K; Wu YI; Mayer BJ
Oncogene; 2015 May; 34(20):2650-9. PubMed ID: 25043303
[TBL] [Abstract][Full Text] [Related]
6. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
Liang X; Hajivandi M; Veach D; Wisniewski D; Clarkson B; Resh MD; Pope RM
Proteomics; 2006 Aug; 6(16):4554-64. PubMed ID: 16858728
[TBL] [Abstract][Full Text] [Related]
7. The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis.
Lakhanpal GK; Vecchiarelli-Federico LM; Li YJ; Cui JW; Bailey ML; Spaner DE; Dumont DJ; Barber DL; Ben-David Y
Blood; 2010 Jul; 116(3):428-36. PubMed ID: 20445019
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
9. c-Abl phosphorylates Dok1 to promote filopodia during cell spreading.
Woodring PJ; Meisenhelder J; Johnson SA; Zhou GL; Field J; Shah K; Bladt F; Pawson T; Niki M; Pandolfi PP; Wang JY; Hunter T
J Cell Biol; 2004 May; 165(4):493-503. PubMed ID: 15148308
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.
Mokhtari D; Al-Amin A; Turpaev K; Li T; Idevall-Hagren O; Li J; Wuttke A; Fred RG; Ravassard P; Scharfmann R; Tengholm A; Welsh N
Diabetologia; 2013 Jun; 56(6):1327-38. PubMed ID: 23462796
[TBL] [Abstract][Full Text] [Related]
11. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.
Chen JL; Limnander A; Rothman PB
Blood; 2008 Feb; 111(3):1677-85. PubMed ID: 18042805
[TBL] [Abstract][Full Text] [Related]
12. Functional involvement of Akt signaling downstream of Jak1 in v-Abl-induced activation of hematopoietic cells.
Oki S; Limnander A; Danial NN; Rothman PB
Blood; 2002 Aug; 100(3):966-73. PubMed ID: 12130510
[TBL] [Abstract][Full Text] [Related]
13. SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.
Fessler SP; Rosenberg N; Baughn LB
J Virol; 2011 Sep; 85(17):9239-42. PubMed ID: 21697469
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
[TBL] [Abstract][Full Text] [Related]
15. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
16. SHIP negatively regulates IgE + antigen-induced IL-6 production in mast cells by inhibiting NF-kappa B activity.
Kalesnikoff J; Baur N; Leitges M; Hughes MR; Damen JE; Huber M; Krystal G
J Immunol; 2002 May; 168(9):4737-46. PubMed ID: 11971024
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
19. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors.
Sattler M; Salgia R; Shrikhande G; Verma S; Choi JL; Rohrschneider LR; Griffin JD
Oncogene; 1997 Nov; 15(19):2379-84. PubMed ID: 9393882
[TBL] [Abstract][Full Text] [Related]
20. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Yu C; Dai Y; Dent P; Grant S
Cancer Biol Ther; 2002; 1(6):674-82. PubMed ID: 12642693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
